Full-year results were ahead of expectations, with an adjusted EBITDA of £44k versus an expected £350k loss, but helped by the accounting treatment for the sale of Actizone patents to Solvay. Byotrol also announced the acquisition of Medimark Scientific, which sells infection control products for the Animal Health and Human Healthcare markets. The £4.5m consideration (including a two-year £1.8m earnout), implies an EV/EBITDA of 7.1x. The combination not only creates cr
23 Aug 2018
Byotrol - FY 2018 and transformative acquisition
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Byotrol - FY 2018 and transformative acquisition
Byotrol plc (BYOT:LON) | 0.1 0 0.0% | Mkt Cap: 0.57m
- Published:
23 Aug 2018 -
Author:
Mark Brewer -
Pages:
20
Full-year results were ahead of expectations, with an adjusted EBITDA of £44k versus an expected £350k loss, but helped by the accounting treatment for the sale of Actizone patents to Solvay. Byotrol also announced the acquisition of Medimark Scientific, which sells infection control products for the Animal Health and Human Healthcare markets. The £4.5m consideration (including a two-year £1.8m earnout), implies an EV/EBITDA of 7.1x. The combination not only creates cr